Back to home » Top Stories » IAC 2010
XVIII International AIDS Conference
IAC 2010 XVIII International AIDS Conference
Reed Messe Wien
Vienna, Austria
July 18-23, 2010


Fewer Malignancies Seen in Those Taking Selzentry

July 20, 2010

By David Evans

People taking the entry inhibitor Selzentry (maraviroc) were no more likely to develop cancer than people taking either Sustiva (efavirenz) or a placebo, according to a study presented Tuesday, July 20, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.

Concerns based on both actual and theoretical scenarios have been raised since the development of CCR5-blocking entry inhibitors, such as Selzentry. From a factual standpoint, a small cluster of malignancies was seen in an early trial of a Schering entry inhibitor that never made it to market. From a theoretical perspective, researchers have speculated that drugs such as Selzentry, which block the CCR5 coreceptor on CD4 cells, could change the way a person’s immune system seeks out cancerous cells. For this reason, the U.S. Food and Drug Administration (FDA) required Selzentry’s maker to conduct long-term surveillance of people on the drug.

To assess the rate of malignancies in people who’d been in Selzentry clinical trials, Sharon Walmsley, MD, from the University of Toronto and her colleagues examined data from four Selzentry studies, MOTIVATE 1 and 2, MERIT and A4001029. The studies included both treatment experienced individuals and those who hadn’t used antiretroviral (ARV) drugs in the past (treatment naive). In total, Walmsley and her colleagues analyzed data on 1,499 people who took Selzentry, 361 who used Sustiva and 270 who received a placebo.

Walmsley’s team found no evidence that Selzentry increased the risk of developing a malignancy. Numerically, there were no more malignancy cases among those taking Selzentry than those who took either Sustiva or a placebo. In fact, among treatment experienced individuals there were actually fewer malignancies of any type among those who took Selzentry than in those who took a placebo. Similarly, there were fewer cases of non-AIDS-related cancers among treatment naive individuals taking Selzentry than in those taking Sustiva.

“Malignancy rates were generally numerically lower on [Selzentry] than [either Sustiva or placebo],” Walmsley concluded. “This analysis showed no associated increased risk of malignancies with [Selzentry] and, in fact, a decrease in some malignancy types.”

Search: Selzentry, maraviroc, CCR5, malignancy, cancer, Sustiva, efavirenz, Sharon Walmsley

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

More from AIDS2010

HIV/AIDS Complications

July 28, 2010
Global Survey: Stigma, Isolation and Discrimination Still Pervasive
Universal HIV Treatment Access No Guarantee of Health for Socially Disadvantaged
July 27, 2010
OM-85 BV: A Bacterial Vaccine Against Respiratory Problems in People with HIV and COPD?
Low Vitamin D Levels Not Associated With HIV Drugs
July 23, 2010
Longer Duration of HIV Infection Might Increase the Risk of Brain Disorders
Nearly 75 Percent of People With HIV Might Have Bone Problems
July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 21, 2010
Non-AIDS Cancers Occurring at Earlier Age Among People With HIV
Hep C Treatment Effective in HIV Patients With Normal Liver Enzymes
Aging Might Have a Smaller Impact on Immune Function Than Suspected
July 20, 2010
Viramune Boosts Hep C Treatment Efficacy in People With HIV
HIV/HCV Coinfection Further Increases Risk of Bone Fractures
Fewer Malignancies Seen in Those Taking Selzentry

Experimental HIV Drugs

July 23, 2010
More Details of TBR-652’s Antiviral and Anti-Inflammatory Potential Reported
July 22, 2010
ViiV HIV Integrase Inhibitor Performing Well in First-Time Treatment Study
Rilpivirine Has Similar Efficacy and Better Tolerability Than Sustiva
Extended-Release Viramune Has Comparable Safety and Efficacy to Standard Viramune
July 20, 2010
New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains
July 19, 2010
Argos’s Dendritic Cell Therapy Reduces HIV During Treatment Interruption

HIV Transmission and Prevention

July 29, 2010
Prevention Is Failing to Target MSM When They’re Young Enough
July 26, 2010
HPV Cancer Vaccine Effective for Heterosexual, Gay and Bisexual Men
Study Finds PrEP Is Safe in Gay and Bi Men
July 23, 2010
Circumcision Unlikely to Have Major HIV Prevention Benefit Among Gay Men
July 21, 2010
Microbicide Success Story: What It Means and Where We Go Next
MACS: Childhood Sex Abuse and Victimization Linked to Increased HIV Risk
Full-Scale HIV Treatment and Prevention Could Save Millions of Lives
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
HIV Cases in Young People Are Falling Around the World
July 19, 2010
Preliminary Results Suggest Good Safety and Adherence Profile for PrEP

Starting and Switching Treatment

July 22, 2010
Reyataz/Isentress Combo Spares Norvir and Nukes, But Is Integrase Resistance a Concern?
Possibly No Survival Benefit to Starting HIV Treatment at CD4s of 500 or More
Once-Daily Prezista/Norvir Monotherapy Largely Effective Over 96 Weeks
Abacavir/Lamivudine Equivalent to Tenofovir/Emtricitabine in Canadian Cohort Study
July 19, 2010
Strategies for a Cure Reviewed in Vienna
Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment
Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects
Protease Inhibitor-to-Isentress Switch is Effective, Lipid Friendly


July 22, 2010
Health Care Providers and People With HIV Not Communicating Effectively
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
5.2 Million People With HIV in Low- and Middle-Income Countries Now on Treatment
At Least 31 Countries Deporting People Living With HIV
HIV Cases in Young People Are Falling Around the World

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.